Values First Advisors’s Relay Therapeutics RLAY Stock Holding History

Values First Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,579	Closed	-$74.9K	–	278
2024 Q3	$74.9K	Buy	+10,579	New	+$79K	0.04%	208

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Values First Advisors's RLAY Position: Q4 2024 in Review

Values First Advisors sold out of Relay Therapeutics (RLAY) in Q4 2024, closing a stake of 10,579 shares — an estimated $74.9K sold.

Values First Advisors first reported a position in RLAY in Q3 2024 and held it in 1 quarter. The position peaked at $74.9K in Q3 2024. 199 funds tracked by Wall St. Rank hold RLAY as of Q4 2024.

Values First Advisors reported no remaining Relay Therapeutics position as of Q4 2024 after selling out during the quarter.
Values First Advisors sold 10,579 Relay Therapeutics shares in Q4 2024, an estimated $74.9K.
Values First Advisors first reported a position in Relay Therapeutics in Q3 2024 and held it in 1 quarter.
Values First Advisors's Relay Therapeutics position peaked at $74.9K in Q3 2024.
199 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2024.

Based on Values First Advisors's 13F filing for Q4 2024, filed 29 Jan 2025.